Search

Your search keyword '"Nicolas Martinez-Calle"' showing total 14 results
Start Over Author "Nicolas Martinez-Calle" Publication Year Range Last 3 years
14 results on '"Nicolas Martinez-Calle"'

1. Allogeneic hematopoietic stem cell transplantation outcome in oldest known surviving patients with Wiskott-Aldrich syndrome

Author

Ariharan Anantharachagan, MBChB, MRCP, MsC,FRCPath, Sook Yin Loh, MBBCh, MRCP, Siobhan O. Burns, MB PhD, Arian Laurence, PhD, MRCP, FRCPath, Susan Tadros, MBBS, BSc, MRCP, FRCPath, Eleni Tholouli, MD, PhD, Yadanar Lwin, MBBS, MMed (Infn, Imm), FRACP, FRCPA, Nicolas Martinez-Calle, MD, PhD, P. Vaitla, MBBS, MRCP, FRCPath, and Emma C. Morris, PhD, FMedSci

Subjects
Wiskott-Aldrich syndrome, WAS, hematopoietic stem cell transplantation, HSCT, adult, Immunologic diseases. Allergy, RC581-607
Abstract

Regardless of their age, adult patients with Wiskott-Aldrich syndrome should be considered for hematopoietic stem cell transplantation if clinically indicated.

Published
2024
Full Text
View/download PDF

3. International multicenter retrospective analysis of thiotepa-based autologous stem cell transplantation for secondary central nervous system lymphoma

Author

Jahanzaib Khwaja, Amy A. Kirkwood, Lisa K. Isbell, Sara Steffanoni, Harshita Goradia, Lisa Pospiech, Thomas Fail, Emma Nicholson, Kate Fletcher, Kim M. Linton, Katrina E. Parsons, Nagah Elmusharaf, Lydia Eccersley, Toby A. Eyre, Sridhar Chaganti, Jeffrey Smith, Nisha Thakrar, Alexandra Kutilina, Teresa Calimeri, Nicolas Martinez-Calle, Dima El-Sharkawi, Wendy Osborne, Gerald Illerhaus, Christopher P. Fox, Andrés J.M. Ferreri, Elisabeth Schorb, and Kate Cwynarski

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2022
Full Text
View/download PDF

4. P015: Real World Escalated BEACOPDac Delivers Similar Outcomes to Escalated BEACOPP While Potentially Reducing Haematopoietic and Reproductive Toxicity

Author

Anna Santarsieri, Katherine Sturgess, Pauline Brice, Tobias F. Menne, Wendy Osborne, Thomas Creasey, Kirit M. Ardeshna, Sarah Behan, Kaljit Bhuller, Stephen Booth, Nikesh Chavda, Graham P. Collins, Dominic Culligan, Kate Cwynarski, Andrew Davies, David Dutton, Michelle Furtado, Eve Gallop-Evans, Andrew Hodson, David Hopkins, Hannah Hsu, Sunil Iyengar, Stephen G. Jones, Kim Linton, Oliver Lomas, Nicolas Martinez-Calle, Abhinav Mathur, Pamela Mckay, Sateesh K. Nagumantry, Deidre O’Mahony, Beth Phillips, Neil Phillips, John F. Rudge, Nimish Shah, Gwyneth Stafford, Alex Sternberg, Rachel Trickey, Benjamin J. Uttenthal, Natasha Wetherall, Andrew K. Mcmillan, and George A. Follows

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2022
Full Text
View/download PDF

5. Replacing Procarbazine with Dacarbazine in Escalated Beacopp Dramatically Reduces the Post Treatment Haematopoietic Stem and Progenitor Cell Mutational Burden in Hodgkin Lymphoma Patients with No Apparent Loss of Clinical Efficacy

Author

Anna Santarsieri, Emily Mitchell, Katherine Sturgess, Pauline Brice, Tobias F. Menne, Wendy Osborne, Thomas Creasey, Kirit M. Ardeshna, Sarah Behan, Kaljit Bhuller, Stephen Booth, Nikesh D. Chavda, Graham P. Collins, Dominic J. Culligan, Kate Cwynarski, Andrew Davies, Abigail Downing, David Dutton, Michelle Furtado, Eve Gallop-Evans, Andrew Hodson, David Hopkins, Hannah Hsu, Sunil Iyengar, Stephen G. Jones, Kim M. Linton, Oliver C. Lomas, Nicolas Martinez-Calle, Abhinav Mathur, Pamela McKay, Sateesh K. Nagumantry, Deirdre O'Mahony, Elizabeth H. Phillips, Neil Phillips, John F. Rudge, Nimish K. Shah, Gwyneth Stafford, Alex Sternberg, Rachel Trickey, Benjamin J. Uttenthal, Natasha Wetherall, Andrew K. McMillan, Michael Stratton, Elisa Laurenti, Peter J. Campbell, and George A. Follows

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022
Full Text
View/download PDF

6. Impact of Double Expression of MYC and BCL-2 on Outcomes in Primary CNS Lymphoma: A UK Multicentre Analysis

Author

Edward Poynton, Emily Chernucha, James Day, Catherine Prodger, David Hopkins, Pallav Rakesh, Tess O'Neill, Nisha Thakrar, Ayse Akarca, Sabine Pomplun, Teresa Marafioti, Maria Calaminici, Sridhar Chaganti, Pam McKay, Jeffery Smith, Toby A. Eyre, Nicolas Martinez-Calle, Kate Cwynarski, Christopher P. Fox, and Jessica Okosun

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022
Full Text
View/download PDF

8. Data from Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy

Author

Toby A. Eyre, John N. Allan, Bruce D. Cheson, Kayla Bigelow, Colleen Dorsey, Andrew D. Zelenetz, Amber C. King, Julie M. Goodfriend, Chadi Nabhan, Hanna B. Weissbrot, Jason C. Lee, Neil Bailey, Erica B. Bhavsar, Talha Munir, Nicolas Martinez-Calle, Christopher P. Fox, Thomas D. Rodgers, Stephen J. Schuster, Timothy J. Voorhees, Kentson Lam, Rachael Pocock, Othman S. Akhtar, Pratik Shah, Krista M. Isaac, Ariel F. Grajales-Cruz, Sirin Khajavian, Andrea Sitlinger, Allison M. Winter, Kate J. Whitaker, Christine A. Garcia, Helen Parry, Craig A. Portell, Paul M. Barr, Joanna Rhodes, Catherine C. Coombs, Michael Choi, Bita Fakhri, Satyen Gohil, John M. Pagel, Jeffrey J. Pu, Pallawi Torka, Alan P. Skarbnik, Jacqueline Barrientos, Javier A. Pinilla-Ibarz, Guilherme Fleury Perini, Maryam Sarraf Yazdy, Chaitra S. Ujjani, Mazyar Shadman, Danielle Brander, Nicole Lamanna, Brian T. Hill, Ryan Jacobs, Lindsey E. Roeker, and Anthony R. Mato

Abstract

Purpose:Venetoclax-based therapy is a standard-of-care option in first-line and relapsed/refractory chronic lymphocytic leukemia (CLL). Patient management following venetoclax discontinuation remains nonstandard and poorly understood.Experimental Design:To address this, we conducted a large international study to identify a cohort of 326 patients who discontinued venetoclax and have been subsequently treated. Coprimary endpoints were overall response rate (ORR) and progression-free survival for the post-venetoclax treatments stratified by treatment type [Bruton's tyrosine kinase inhibitor (BTKi), PI3K inhibitor (PI3Ki), and cellular therapies].Results:We identified patients with CLL who discontinued venetoclax in the first-line (4%) and relapsed/refractory settings (96%). Patients received a median of three therapies prior to venetoclax; 40% were BTKi naïve (n = 130), and 81% were idelalisib naïve (n = 263). ORR to BTKi was 84% (n = 44) in BTKi-naïve patients versus 54% (n = 30) in BTKi-exposed patients. We demonstrate therapy selection following venetoclax requires prior novel agent exposure consideration and discontinuation reasons.Conclusions:For BTKi-naïve patients, selection of covalently binding BTKis results in high ORR and durable remissions. For BTKi-exposed patients, covalent BTK inhibition is not effective in the setting of BTKi resistance. PI3Kis following venetoclax do not appear to result in durable remissions. We conclude that BTKi in naïve or previously responsive patients and cellular therapies following venetoclax may be the most effective strategies.See related commentary by Rogers, p. 3501

Published
2023
Full Text
View/download PDF

9. Supplemental Figure 2 from Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy

Author

Toby A. Eyre, John N. Allan, Bruce D. Cheson, Kayla Bigelow, Colleen Dorsey, Andrew D. Zelenetz, Amber C. King, Julie M. Goodfriend, Chadi Nabhan, Hanna B. Weissbrot, Jason C. Lee, Neil Bailey, Erica B. Bhavsar, Talha Munir, Nicolas Martinez-Calle, Christopher P. Fox, Thomas D. Rodgers, Stephen J. Schuster, Timothy J. Voorhees, Kentson Lam, Rachael Pocock, Othman S. Akhtar, Pratik Shah, Krista M. Isaac, Ariel F. Grajales-Cruz, Sirin Khajavian, Andrea Sitlinger, Allison M. Winter, Kate J. Whitaker, Christine A. Garcia, Helen Parry, Craig A. Portell, Paul M. Barr, Joanna Rhodes, Catherine C. Coombs, Michael Choi, Bita Fakhri, Satyen Gohil, John M. Pagel, Jeffrey J. Pu, Pallawi Torka, Alan P. Skarbnik, Jacqueline Barrientos, Javier A. Pinilla-Ibarz, Guilherme Fleury Perini, Maryam Sarraf Yazdy, Chaitra S. Ujjani, Mazyar Shadman, Danielle Brander, Nicole Lamanna, Brian T. Hill, Ryan Jacobs, Lindsey E. Roeker, and Anthony R. Mato

Abstract

Supplemental Figure 2: Progression free survival of patients without prior BTKi exposure who had progressed on venetoclax and were then treated with BTKi.

Published
2023
Full Text
View/download PDF

10. Supplemental Figure 1 from Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy

Author

Toby A. Eyre, John N. Allan, Bruce D. Cheson, Kayla Bigelow, Colleen Dorsey, Andrew D. Zelenetz, Amber C. King, Julie M. Goodfriend, Chadi Nabhan, Hanna B. Weissbrot, Jason C. Lee, Neil Bailey, Erica B. Bhavsar, Talha Munir, Nicolas Martinez-Calle, Christopher P. Fox, Thomas D. Rodgers, Stephen J. Schuster, Timothy J. Voorhees, Kentson Lam, Rachael Pocock, Othman S. Akhtar, Pratik Shah, Krista M. Isaac, Ariel F. Grajales-Cruz, Sirin Khajavian, Andrea Sitlinger, Allison M. Winter, Kate J. Whitaker, Christine A. Garcia, Helen Parry, Craig A. Portell, Paul M. Barr, Joanna Rhodes, Catherine C. Coombs, Michael Choi, Bita Fakhri, Satyen Gohil, John M. Pagel, Jeffrey J. Pu, Pallawi Torka, Alan P. Skarbnik, Jacqueline Barrientos, Javier A. Pinilla-Ibarz, Guilherme Fleury Perini, Maryam Sarraf Yazdy, Chaitra S. Ujjani, Mazyar Shadman, Danielle Brander, Nicole Lamanna, Brian T. Hill, Ryan Jacobs, Lindsey E. Roeker, and Anthony R. Mato

Abstract

Supplemental Figure 1: Overall survival of entire cohort from initiation of venetoclax.

Published
2023
Full Text
View/download PDF

11. Venetoclax ramp‐up strategies for <scp>chronic lymphocytic leukaemia</scp> in the <scp>United Kingdom</scp> : a real world multicentre retrospective study

Author

Rocio Figueroa‐Mora, Alexandros Rampotas, Daniel Halperin, Tina Worth, Jennifer Vidler, Dario Melotti, Paul Ferguson, Nagah Elmusharaf, Gavin Preston, Michelle Furtado, Moez Dungarwalla, Satyen Gohill, Piers Patten, Ben Kennedy, Toby A. Eyre, Anna Schuh, Christopher P. Fox, Tahla Munir, and Nicolas Martinez‐Calle

Subjects
Hematology
Published
2023
Full Text
View/download PDF

12. A case of idiopathic chylous ascites

Author

Adina Olaru, Suresh V Venkatachalapathy, Martin James, and Nicolas Martinez-Calle

Subjects
Infectious Diseases, Parasitology, Microbiology
Abstract

Chylous ascites is a rare condition found in 1 in 20 000 patients admitted to hospital with abdominal distention. It is caused by a limited number of pathologies but can, in rare situations, be idiopathic. Its management is difficult and usually involves correcting the primary pathology, making idiopathic chylous ascites particularly difficult to manage. We present a case of idiopathic chylous ascites extensively investigated over a period of several years. An incidental finding of B cell lymphoma was initially suspected to have been the primary cause of the ascites; however, after successful treatment of this condition, the patient’s ascites did not resolve. Diagnostic difficulties and management are discussed and an overview of the diagnostic process is outlined through this case.

Published
2023
Full Text
View/download PDF

13. Coronary artery disease and revascularization associated with immune checkpoint blocker myocarditis: Report from an international registry

Author

Joseph Nowatzke, Paul Guedeney, Nicholas Palaskas, Lorenz Lehmann, Stephane Ederhy, Han Zhu, Jennifer Cautela, Sanjeev Francis, Pierre-Yves Courand, Anita Deswal, Steven M. Ewer, Mandar Aras, Dimitri Arangalage, Kambiz Ghafourian, Charlotte Fenioux, Daniel Finke, Giovanni Peretto, Vlad Zaha, Osnat Itzhaki Ben Zadok, Kazuko Tajiri, Nausheen Akhter, Joshua Levenson, Lauren Baldassarre, John Power, Shi Huang, Jean-Philippe Collet, Javid Moslehi, Joe-Elie Salem, Nazanin Aghel, Joachim Alexandre, Kazutaka Aonuma, Aarti H. Asnani, Juliane Behling, Mehmet Bilen, Wendy Bottinor, Eve Cariou, Johnny Chahine, Weiting Chan, Aman Chauhan, Max Cohen, Shanthini Crusz, Suran Fernando, Roberta Florido, Mauro Frigeri, Satoshi Fukushima, Elizabeth Gaughan, Benjamin P. Geisler, Lauren Gilstrap, Christian Grohe, Avirup Guha, Manhal Habib, Eva Haegler-Laube, Andrew Haydon, Salim Hayek, Andrew Hughes, Rysk Imai, Yumi Katsume, Hideki Kimura, Lily Koo Lin, Carrie Lenneman, Daryl Leong, Vicky Makker, Nicolas Martinez-Calle, Melissa Moey, Masahiro Mohri, Ryota Morimoto, Yoshinobu Moritoki, Anna Narezkina, Martin Nicol, Ajay Nooka, Olusola Orimoloye, Milan Patel, Michal Perl, Nicolas Piriou, Jayant K. Raikhelkar, Yasmin Raza, Anjali Rao, Sunil Reddy, Nobuhiko Seki, Karl Stangl, Andrew Stewart, Bryan Stringer, Balaji K. Tamarappoo, Yuichi Tamura, Frank Thuny, Sean Tierney, Romain Tresorier, Waqas Ullah, Jean-Jacques Von Hunolstein, Ellen Warner, Allison Weppler, Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] (IHU ICAN), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut de cardiologie [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Universität Heidelberg [Heidelberg] = Heidelberg University, German Center for Cardiovascular Research (DZHK), Berlin Institute of Health (BIH), CHU Saint-Antoine [AP-HP], Groupe de REcherche en Cardio Oncologie (GRC 27 - GRECO), Sorbonne Université (SU), Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon, Imagerie Ultrasonore, Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé (CREATIS), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), The University of Texas Medical School at Houston, University of Wisconsin-Madison, University of California [San Francisco] (UC San Francisco), University of California (UC), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), University of Heidelberg, Medical Faculty, Division of Endocrinology, Metabolism, and Diabetes, University of Utah, Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases [IHU ICAN], Universität Heidelberg [Heidelberg], Service de Cardiologie [CHU Saint-Antoine], Groupe de REcherche en Cardio Oncologie [CHU Saint-Antoine] (GRC 27 GRECO), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), and Service de Pharmacologie médicale [CHU Pitié-Salpêtrière]

Subjects
Cancer Research, Coronary Artery Disease, Prognosis, Coronary revascularization, Myocarditis, Oncology, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Risk Factors, Immune-related adverse events, [INFO.INFO-IM]Computer Science [cs]/Medical Imaging, Humans, Registries, Immune checkpoint blockers, Acute coronary syndrome, [PHYS.MECA.BIOM]Physics [physics]/Mechanics [physics]/Biomechanics [physics.med-ph], Immune Checkpoint Inhibitors, Retrospective Studies
Abstract

International audience; Purpose: Immune checkpoint blocker (ICB) associated myocarditis (ICB-myocar-ditis) may present similarly and/or overlap with other cardiac pathology including acute cor-onary syndrome presenting a challenge for prompt clinical diagnosis.Methods: An international registry was used to retrospectively identify cases of ICB-myocarditis. Presence of coronary artery disease (CAD) was defined as coronary artery steno-sis >70% in patients undergoing coronary angiogram.Results: Among 261 patients with clinically suspected ICB-myocarditis who underwent a coro-nary angiography, CAD was present in 59/261 patients (22.6%). Coronary revascularization was performed during the index hospitalisation in 19/59 (32.2%) patients. Patients undergoing coro-nary revascularization less frequently received steroids administration within 24 h of admission compared to the other groups (p = 0.029). Myocarditis-related 90-day mortality was 9/17 (52.7%) in the revascularised cohort, compared to 5/31 (16.1%) in those not revascularized and 25/156 (16.0%) in those without CAD (p = 0.001). Immune-related adverse event-related 90-day mortality was 9/17 (52.7%) in the revascularized cohort, compared to 6/31 (19.4%) in those not revascularized and 31/156 (19.9%) in no CAD groups (p = 0.007). All-cause 90-day mortality was 11/17 (64.7%) in the revascularized cohort, compared to 13/31 (41.9%) in no revas-cularization and 60/158 (38.0%) in no CAD groups (p = 0.10). After adjustment of age and sex, coronary revascularization remained associated with ICB-myocarditis-related death at 90 days (hazard ratio [HR] = 4.03, 95% confidence interval [CI] 1.84-8.84, p < 0.001) and was margin-ally associated with all-cause death (HR = 1.88, 95% CI, 0.98-3.61, p = 0.057).Conclusion: CAD may exist concomitantly with ICB-myocarditis and may portend a poorer outcome when revascularization is performed. This is potentially mediated through delayed diag-nosis and treatment or more severe presentation of ICB-myocarditis.

Published
2022
Full Text
View/download PDF

14. Epigenetic-based differentiation therapy for Acute Myeloid Leukemia

Author

Edurne San José-Enériz, Naroa Gimenez-Camino, Obdulia Rabal, Leire Garate, Estibaliz Miranda, Nahia Gómez-Echarte, Fernando García, Stella Charalampopoulou, Elena Sáez, Amaia Vilas-Zornoza, Patxi San Martín-Uriz, Luis V. Valcárcel, Naroa Barrena, Diego Alignani, Luis Esteban Tamariz-Amador, Ana Pérez-Ruiz, Sebastian Hilscher, Mike Schutkowski, Ana Alfonso-Pierola, Nicolás Martinez-Calle, María José Larrayoz, Bruno Paiva, María José Calasanz, Javier Muñoz, Marta Isasa, José Ignacio Martin-Subero, Antonio Pineda-Lucena, Julen Oyarzabal, Xabier Agirre, and Felipe Prósper

Subjects
Science
Abstract

Abstract Despite the development of novel therapies for acute myeloid leukemia, outcomes remain poor for most patients, and therapeutic improvements are an urgent unmet need. Although treatment regimens promoting differentiation have succeeded in the treatment of acute promyelocytic leukemia, their role in other acute myeloid leukemia subtypes needs to be explored. Here we identify and characterize two lysine deacetylase inhibitors, CM-444 and CM-1758, exhibiting the capacity to promote myeloid differentiation in all acute myeloid leukemia subtypes at low non-cytotoxic doses, unlike other commercial histone deacetylase inhibitors. Analyzing the acetylome after CM-444 and CM-1758 treatment reveals modulation of non-histone proteins involved in the enhancer–promoter chromatin regulatory complex, including bromodomain proteins. This acetylation is essential for enhancing the expression of key transcription factors directly involved in the differentiation therapy induced by CM-444/CM-1758 in acute myeloid leukemia. In summary, these compounds may represent effective differentiation-based therapeutic agents across acute myeloid leukemia subtypes with a potential mechanism for the treatment of acute myeloid leukemia.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results